Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy - Wikidata - awgldk - TriplyDB

Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy

Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy

http://www.wikidata.org/entity/Q35405149

about

Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy Pericytes derived from adipose-derived stem cells protect against retinal vasculopathy.Toll-like receptor 4 in bone marrow-derived cells contributes to the progression of diabetic retinopathy.A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice.RAGE regulates immune cell infiltration and angiogenesis in choroidal neovascularization.ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Systemic treatment with erythropoietin protects the neurovascular unit in a rat model of retinal neurodegeneration Systemic administration of erythropoietin inhibits retinopathy in RCS rats.Role of the receptor for advanced glycation endproducts (RAGE) in retinal vasodegenerative pathology during diabetes in mice.Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury.Nonerythropoietic Erythropoietin-Derived Peptide Suppresses Adipogenesis, Inflammation, Obesity and Insulin Resistance.The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy Experimental study of the protective effects of SYVN1 against diabetic retinopathy Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy.Treatment of mild traumatic brain injury with an erythropoietin-mimetic peptide Genetics in diabetic retinopathy: current concepts and new insights.In vivo retinal vascular oxygen tension imaging and fluorescein angiography in the mouse model of oxygen-induced retinopathy Animal models of diabetic retinopathy: summary and comparison.Hypoxia-Inducible Factor-1α Target Genes Contribute to Retinal Neuroprotection.Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy.Novel targets against retinal angiogenesis in diabetic retinopathy.Neuropeptides and diabetic retinopathy.Advances in our understanding of diabetic retinopathy.Candidate genes for proliferative diabetic retinopathy.Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment.Friend or Foe? Resident Microglia vs Bone Marrow-Derived Microglia and Their Roles in the Retinal Degeneration.Revisiting the role of erythropoietin for treatment of ocular disorders.Growth Factors in the Pathogenesis of Retinal Neurodegeneration in Diabetes Mellitus Association of erythropoietin gene polymorphisms with retinopathy in a Chinese cohort with type 2 diabetes mellitus.Angiogenic Factors and Cytokines in Diabetic Retinopathy.Inflammatory demyelination induces glia alterations and ganglion cell loss in the retina of an experimental autoimmune encephalomyelitis model.Neural inflammation and the microglial response in diabetic retinopathy.Neurodegeneration in diabetic retina and its potential drug targets.Cyclic helix B peptide protects HK‑2 cells from oxidative stress by inhibiting ER stress and activating Nrf2 signalling and autophagy.Serine racemase deletion attenuates neurodegeneration and microvascular damage in diabetic retinopathy.The Role of Microglia in Diabetic Retinopathy: Inflammation, Microvasculature Defects and Neurodegeneration.Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus.Diabetic Retinopathy: Pathophysiology and Treatments.

P2860

Q26866295-6555EA70-BA65-4B8B-9FD1-2688B86D6542 Q28262797-A7BFB689-2CEC-4E4E-B17B-ADFCBD7A8556 Q30418921-2617F6FB-CD1A-4EA1-829B-68DF9EA9AAC7 Q34145920-C68C624D-F7CF-42DF-B3FF-B6E7BCA0CCDE Q34914262-0B800C32-55EA-46F9-AF67-4E96E4894A33 Q35107593-7A012BAD-D116-4A78-905D-44ABE2AB62AB Q35192848-BC772965-EBDA-4DD8-816B-D5D8CC3EBF93 Q35205276-39D0A83C-BF12-4986-8E37-4B57F3C451D7 Q35224135-DF50F563-DA8C-4B47-8327-CFE62ABAD872 Q35350451-411FB3BA-9EDA-48F6-B998-44566B674585 Q36071692-0C3CAB18-98E8-4655-B0FA-EBB3ABBBC495 Q36150300-C9BE760E-A667-4694-BF5C-AC888C10EEAE Q36220047-ED731DD5-DF97-4753-8782-72F97DE480E2 Q36273653-F995C4B2-32A5-4646-B39F-3580426B44B4 Q36494891-60AD7D27-C3AC-4724-905B-8404677ECA2D Q36842139-38F63871-5991-44A2-B49E-90C1BA9D44B8 Q37148800-FC408AC5-6B31-4A1B-901E-E63FF02736DE Q37254753-97F38386-C06C-423D-A556-67FB11C0AFBA Q37304677-635E3428-8762-4F97-AF37-458DF248D883 Q37667292-C2AB546F-9988-46A9-B028-084F19FB3FF5 Q37968179-50F28F7B-9992-41C2-9DEE-262D2AF4DA3E Q38013679-9B1C67E3-DE9F-4A11-A93D-2C72E75CA0E2 Q38050159-649771D9-C2BC-4877-9E3D-16BBB610A398 Q38088818-5D51276F-3755-4E23-B4B6-3B851A65F79D Q38143091-2AF0B674-4F48-4ACD-8F59-03B5F5D8D21E Q38199730-8BEDE031-5959-4F79-B603-2B2160A1A87E Q38851309-42F6F1ED-04F1-4DE9-8631-436585A72A59 Q38855251-3F302980-8E3D-4D6A-9FDF-B1F24E96B8EE Q38928508-1C426076-6186-4BA4-9B20-A9EFAC44E2BC Q41444553-2B978A19-5F50-40CE-BEA1-5830855441FE Q41883466-9C8FF8C7-CBC4-42DD-804F-F643099E40AA Q41905360-0C4EAC9A-BE64-4B74-B98E-C52DEFA456D3 Q42144753-81BE6216-EC17-4276-BE38-6CE2E1763B91 Q42957709-B3AB1AA8-244D-46A1-9CC3-8FCA115E287E Q46301304-E704A05A-A05C-44FF-B39E-1E4E8FFAB926 Q48303123-AD041E6D-4C6A-4BD1-B577-BB596D4A3197 Q48308877-8A919682-16F5-429C-A754-671BDC141ECC Q55400853-56B633C4-C847-4774-B29B-861A5B874717 Q55711452-324D0874-D04F-45DE-A1B6-3CC1B4E3FFEA

P2860

Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy

http://www.wikidata.org/entity/Q35405149

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Intervention with an erythropo ...... on during diabetic retinopathy

@ast

Intervention with an erythropo ...... on during diabetic retinopathy

@en

type

label

Intervention with an erythropo ...... on during diabetic retinopathy

@ast

Intervention with an erythropo ...... on during diabetic retinopathy

@en

prefLabel

Intervention with an erythropo ...... on during diabetic retinopathy

@ast

Intervention with an erythropo ...... on during diabetic retinopathy

@en

P1433

Q35405149-85E045BA-8508-4CCE-8725-0B4381065A9E

P1476

Q35405149-EAEA8490-EC61-4F41-9231-FDE40071F5F9

P2093

Q35405149-06CD3F10-D552-4470-B45B-B9AC75A4FF8F

Q35405149-235EA473-7712-424F-87D9-5005632B6C45

Q35405149-522E6882-E3B4-4FCF-B387-61E210F2BCDD

Q35405149-89D55436-1D13-41AA-88E6-CF83C7DA0F88

Q35405149-91CF1BE1-3972-4FD4-9694-25BBC5B7E582

Q35405149-93573E7E-E560-41A4-9CE2-BFDBEE84D3C0

Q35405149-B3DF4C36-860C-4C41-B1E2-662796C3A1EC

P2860

Q35405149-0ACC29D6-9631-4338-B096-16D443D84688

Q35405149-0B4CC6BE-D17D-471D-A204-F88EBDDE7141

Q35405149-0F329CBC-8251-4899-AA39-D40CF12C89B1

Q35405149-138BE8FF-847E-486B-8B96-5D182752C748

Q35405149-18989AB5-79DB-4BAE-9FAF-333013E89653

Q35405149-1C8250F4-7D1F-4A84-8BD7-DBF71ABB5D7A

Q35405149-217D314A-17A6-4815-B588-26C8CBEC5FCC

Q35405149-273D065C-2CF6-4A90-8FC6-F94B7E3BE244

Q35405149-2E92E932-DBD7-4E58-BE69-A9FF9A52D930

Q35405149-2F02A88C-2F6B-4AF2-B954-2452C6360243

P304

Q35405149-BFFF396B-D0CD-4065-B13C-D782510A8726

P31

Q35405149-1BCB5DDD-151D-4E93-B137-D5FE652E1ACE

P356

Q35405149-BCAB0636-96CB-4A3C-ABD6-FC508402C756

P407

Q35405149-A3C904B6-5F36-4C46-A5E4-9CF80DA7BAF1

P433

Q35405149-E99F1114-9D9C-41D7-927E-115CF7E9EBAA

P478

Q35405149-BA91BFE9-A658-42CB-B3B7-58D0E98DDD0B

P577

Q35405149-71EE23CF-393D-45B1-B035-2A5B0C02E4C4

P5875

Q35405149-1A3914DC-D75D-4986-862F-20DAB7DF41AA

P698

Q35405149-89273E89-4825-4888-A1A4-BA5FB6BC5B80

P921

Q35405149-F4171F37-B458-4CFE-A3AC-265B9020127F

P932

Q35405149-6BD322CA-737F-4AE7-8DE3-2728ED301017

P356

P1433

P1476

Intervention with an erythropo ...... on during diabetic retinopathy

@en

P2093

Alan W Stitt

http://www.w3.org/2001/XMLSchema#string

Anthony Cerami

http://www.w3.org/2001/XMLSchema#string

Carmel M McVicar

http://www.w3.org/2001/XMLSchema#string

Liza M Colhoun

http://www.w3.org/2001/XMLSchema#string

Michael Brines

http://www.w3.org/2001/XMLSchema#string

Ross Hamilton

http://www.w3.org/2001/XMLSchema#string

Tom A Gardiner

http://www.w3.org/2001/XMLSchema#string

P2860

Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress

Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy

Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.

Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy

HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration.

New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets.

Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Leading causes of blindness worldwide.

Survival and proliferative roles of erythropoietin beyond the erythroid lineage.

Non-erythroid functions of erythropoietin.

P304

2995-3005

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB11-0026

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51641318

http://www.w3.org/2001/XMLSchema#string

P698

21911748

http://www.w3.org/2001/XMLSchema#string

P921

P932

3198080

http://www.w3.org/2001/XMLSchema#string